05/04 | KURA ONCOLOGY : Q1 Earnings Snapshot | AQ |
05/04 | KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE.. | AQ |
05/04 | TRANSCRIPT : Kura Oncology, Inc., Q1 2022 Earnings Call, May 04, 2022 | CI |
05/04 | Kura Oncology Reports First Quarter 2022 Financial Results | AQ |
05/04 | Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
04/27 | Kura Oncology to Report First Quarter 2022 Financial Results | AQ |
04/08 | Kura Oncology Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergenc.. | AQ |
04/08 | Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Em.. | CI |
03/15 | TRANSCRIPT : Kura Oncology, Inc. Presents at Barclays Global Healthcare Conference 2022, M.. | CI |
03/08 | Kura Oncology Announces Multiple Abstracts Accepted for Presentation at AACR Annual Mee.. | AQ |
02/28 | Kura Oncology to Participate in Two Upcoming Investor Conferences | AQ |
02/25 | SVB Leerink Lowers Kura Oncology's Price Target to $28 From $41, Maintains Outperform R.. | MT |
02/25 | Credit Suisse Lifts Kura Oncology's Price Target to $27 from $25, Notes Rich Catalyst L.. | MT |
02/24 | KURA ONCOLOGY, INC. : Entry into a Material Definitive Agreement, Termination of a Materia.. | AQ |
02/24 | KURA ONCOLOGY : Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K | PU |
02/24 | KURA ONCOLOGY : Q4 Earnings Snapshot | AQ |
02/24 | TRANSCRIPT : Kura Oncology, Inc., Q4 2021 Earnings Call, Feb 24, 2022 | CI |
02/24 | KURA ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Re.. | AQ |
02/24 | Kura Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
02/24 | Kura Oncology Reports Fourth Quarter and Full Year 2021 Financial Results | AQ |
02/24 | Kura Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, .. | CI |
02/17 | Kura Oncology to Report Fourth Quarter and Full Year 2021 Financial Results | AQ |
02/15 | Jefferies Financial Initiates Kura Oncology at Buy, Sets Price Target at $35 | MT |
02/14 | Credit Suisse Lifts Kura Oncology's Price Target to $25 from $21, Maintains Outperform .. | MT |
02/10 | Kura Oncology to Participate in SVB Leerink Global Healthcare Conference | GL |
02/07 | Alector Appoints Marc Grasso as CFO | MT |
02/02 | Kura Oncology Finance Chief Marc Grasso to Step Down | MT |
02/01 | KURA ONCOLOGY, INC. : Change in Directors or Principal Officers (form 8-K) | AQ |
02/01 | Kura Oncology Expands Leadership Team with Key Promotions | GL |
02/01 | Kura Oncology, Inc. Announces Executive Changes | CI |
02/01 | Kura Oncology, Inc. Announces Executive Changes | CI |
01/21 | Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Ac.. | AQ |
01/20 | FDA Lifts Hold Kura Oncology's KOMET-001 Phase 1b Study of KO-539 Patients With Relapse.. | MT |
01/20 | KURA ONCOLOGY, INC. : Other Events (form 8-K) | AQ |
01/20 | Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Ac.. | AQ |
01/20 | Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539.. | CI |
2021 | Kura Oncology Initiates Dosing in Phase 1/2 Clinical Trial of Head, Neck Cancer Combo T.. | MT |
2021 | Kura Oncology Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combinat.. | GL |
2021 | Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Co.. | CI |
2021 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kura .. | PR |
2021 | Kura Oncology Reports 56% Overall Response Rate in T-Cell Lymphoma Drug Study | MT |
2021 | Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma | AQ |
2021 | Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Ly.. | CI |
2021 | Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Menin Inhib.. | GL |
2021 | Credit Suisse Adjusts Kura Oncology's Price Target to $21 From $40, Keeps Outperform Ra.. | MT |
2021 | Health Care Stocks Unable to Return to Positive Ground By Wednesday Close | MT |
2021 | Kura Oncology Shares Sink After FDA Imposes Partial Hold on Phase 1b Study of KO-539 | MT |
2021 | Health Care Stocks Marginally Lower After Paring Losses | MT |
2021 | HC Wainwright Adjusts Price Target on Kura Oncology to $32 From $43, Maintains Buy Rati.. | MT |
2021 | Wedbush Cuts Kura Oncology's Price Target to $40 From $53 After KO-539 Partial Clinical.. | MT |
2021 | Wall Street Set to Open in Red Territory; US GDP Growth Upwardly Revised in Q3 | MT |
2021 | Health Care Stocks Mixed Premarket Wednesday | MT |
2021 | Health Care | MT |
2021 | TRANSCRIPT : Kura Oncology, Inc. - Special Call | CI |
2021 | Top Premarket Decliners | MT |
2021 | Kura Oncology Says US FDA Places Study of KO-539 on Partial Hold Following Patient Deat.. | MT |
2021 | KURA ONCOLOGY, INC. : Other Events (form 8-K) | AQ |
2021 | Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia | AQ |
2021 | Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia | CI |
2021 | Kura Oncology to Participate in Two Upcoming Investor Conferences | GL |
2021 | TRANSCRIPT : Kura Oncology, Inc. Presents at 30th Annual Credit Suisse Healthcare Conferen.. | CI |
2021 | KURA ONCOLOGY : Q3 Earnings Snapshot | AQ |
2021 | Kura Oncology Reports Third Quarter 2021 Financial Results - Form 8-K | PU |
2021 | Kura Oncology - Corporate Presentation - November 2021 | PU |
2021 | TRANSCRIPT : Kura Oncology, Inc., Q3 2021 Earnings Call, Nov 04, 2021 | CI |
2021 | KURA ONCOLOGY, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE.. | AQ |
2021 | Kura Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende.. | CI |
2021 | Kura Oncology Reports Third Quarter 2021 Financial Results | AQ |
2021 | Kura Oncology to Participate in Credit Suisse Healthcare Conference | GL |
2021 | Kura Oncology to Report Third Quarter 2021 Financial Results | GL |
2021 | KURA ONCOLOGY : Appoints Teresa Bair as Chief Legal Officer | AQ |
2021 | KURA ONCOLOGY : Appoints Teresa Bair as Chief Legal Officer | GL |
2021 | Kura Oncology, Inc. Appoints Teresa Bair as Chief Legal Officer | CI |
2021 | KURA ONCOLOGY : Corporate Presentation - September 2021 | PU |
2021 | KURA ONCOLOGY : to Participate in Two Upcoming Investor Conferences | AQ |